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Abstract
Infectious diseases and underlying medical conditions common to Africa may affect influen-
za frequency and severity. We conducted a systematic review of published studies on influ-
enza and the following co-infections or co-morbidities that are prevalent in Africa: dengue,
malaria, measles, meningococcus, Pneumocystis jirovecii pneumonia (PCP), hemoglobin-
opathies, and malnutrition. Articles were identified except for influenza and PCP. Very few
studies were from Africa. Sickle cell disease, dengue, and measles co-infection were found
to increase the severity of influenza disease, though this is based on few studies of dengue
and measles and the measles study was of low quality. The frequency of influenza was in-
creased among patients with sickle cell disease. Influenza infection increased the frequency
of meningococcal disease. Studies on malaria and malnutrition found mixed results. Age-
adjusted morbidity and mortality from influenza may be more common in Africa because in-
fections and diseases common in the region lead to more severe outcomes and increase
the influenza burden. However, gaps exist in our knowledge about these interactions.
Introduction
Until recently, little was known about influenza in Africa except for outbreaks reporting a high
case-fatality rate [1–4]. In response to threats from avian and pandemic influenza, surveillance
has expanded in recent years, and from 2006–2010, influenza surveillance sites increased more
than tenfold across the continent [5]. Recent studies have suggested that influenza is common
in Africa. Much of the global burden of severe influenza is in less developed countries [6], and
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during the 2009 influenza pandemic, Africa may have borne a disproportionate number of
deaths from influenza [7].
There are a number of reasons why sub-Saharan Africa specifically may share a dispropor-
tionate burden of severe disease outcomes from influenza and should be a focus of interven-
tions to reduce the global burden of disease. One of these is the high prevalence of co-
infections and co-morbidities that may be risk factors for more severe influenza illness, such as
HIV and tuberculosis [8]. Another important co-infection may be dengue, which is under-rec-
ognized and underreported in Africa; it is estimated that as many as 1 million cases occur in
Africa annually and 22 countries have reported sporadic cases or outbreaks [9]. Of the more
than 600,000 deaths from malaria in 2012, 90% occurred in sub-Saharan Africa [10]. Measles is
common in Africa, and N.meningitidis causes recurring meningitis epidemics in the sub-Saha-
ran meningitis belt. Pneumocystis jirovecii pneumonia (PCP) is the most common opportunis-
tic infection among HIV-infected individuals and may be a common cause of respiratory
illness in much of sub-Saharan Africa where HIV is prevalent [11]. In 2010, more than 230,000
infants were estimated to be born with sickle cell disease in sub-Saharan Africa, and more than
3.6 million infants were born with sickle cell trait, more than two-thirds of the global burden of
disease [12]. The World Health Organization estimates that malnutrition contributes to a third
of all deaths in children under five years, and many of these deaths are in sub-Saharan Africa
[13].
Little is known about whether co-infections and co-morbidities which are prevalent in Af-
rica have the potential to increase the frequency or severity of influenza infection or to affect re-
sponse to influenza vaccination. Co-infection of influenza with HIV, tuberculosis, and
pneumococcus has been established as causes of severe disease in Africa and have been ex-
plored recently in the literature [14–18]. The impact of underlying medical conditions such as
diabetes mellitus and asthma on influenza has been explored extensively in the global literature
[19]. We conducted a systematic review of published studies to fill the gaps in knowledge of
other co-infections and co-morbidities that could also plausibly influence influenza burden in
Africa.
Materials and Methods
We conducted systematic reviews of the literature published from January 1900 to August
2013. Seven databases were searched: Medline [Ovid], Embase, PsycINFO, CINAHL, Web of
Science, Cochrane, Global Health, Google Scholar, and CAB Abstracts. Studies were included
if they contained original data on the following:
1. Frequency or burden of influenza and co-infection or co-morbidity
2. Disease association between influenza and co-infection or co-morbidity
3. Clinical presentation of influenza and co-infection or co-morbidity
4. Effectiveness of interventions preventing laboratory-confirmed influenza among individuals
with the co-infection or co-morbidity
Eligible studies had to be conducted in humans and could be of any study design except case
studies. Summary measures gathered as part of the review differed by study design; when avail-
able, relative risks, odds ratios (OR), and percents of seroconversion or seroprotection after in-
fluenza vaccination were abstracted. Studies could be conducted in any country or setting but
needed to be written in English, Spanish, French, Portuguese, Italian, or German.
Databases were last searched in September 2013. The titles of all studies identified through
the database searches were reviewed by two reviewers; the abstracts and full text of potentially
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relevant articles were then reviewed. Additional articles were identified from reviewing bibliog-
raphies of published articles.
Seven separate systematic reviews were conducted and reported according to PRISMA
Statement guidelines [20]. The topics of the reviews were chosen among infections and mor-
bidities with the following two characteristics: (1) they are prevalent or emerging infections or
underlying medical conditions in African countries, and (2) an association with influenza is
plausible but not well-accepted or recently reviewed in the literature. The topics of the reviews
included in this paper were not intended to be comprehensive nor specific to Africa; they were
chosen to fill in research gaps for conditions for which little is known and which might impact
influenza in Africa. The seven infections and morbidities in this review were dengue, malaria,
measles, meningococcal disease, PCP, hemoglobinopathies, and malnutrition. For each search,
we included (1) a term for influenza (“influenza” or “flu”) and (2) a term for each co-infection
or co-morbidity, as listed below. Variations on words were also included, e.g., “parasite” and
“parasitology,” depending on the database. The search strategy differed slightly depending on
the database. Search terms for co-infections and co-morbidities included in this review were as
follows:
1. Malaria: malaria, Plasmodium or parasite
2. Malnutrition: Malnutrition, kwashiorkor, marasmus, or nutrition
3. Hemoglobinopathies: Hemoglobinopathy, sickle cell, hemoglobin SC, hemoglobin C,
or thalassemia
4. Meningococcal Disease: Neisseria meningitides or meningococcus
5. Dengue: Dengue
6. Measles: Measles
7. Pneumocystis jirovecii pneumonia: Pneumocystis
Several studies were identified that assessed probiotics or other nutritional supplements not
traditionally found in resource-limited settings; therefore, we restricted inclusion criteria for
these malnutrition articles to nutritional supplements that are commonly available in African
settings such as zinc sulfate or Vitamin A. When appropriate, we rated the quality of the indi-
vidual studies using the Newcastle-Ottawa Scale [21]. Studies were considered high quality if
the Newcastle-Ottawa Scale was7 out of 9; studies were of low quality if the score was3 of
9. Individual studies were also assessed for potential bias or confounding. No review protocol




Dengue. Our literature search yielded 1,228 articles of which 287 were duplicates (Fig 1).
Of the remaining 941 articles, 12 were deemed to be potentially relevant and were fully assessed
for eligibility and 2 met selection criteria, both from Nicaragua. Both studies were large cohort
studies of high quality (S1 Table). The 2009 pandemic influenza A(H1N1)pdm09 (pH1N1) co-
incided with the dengue season in Nicaragua, and both studies found that co-infection was as-
sociated with increased illness severity. The first study followed a cohort of children for
influenza A(pH1N1) infection. Of 185 children with influenza A(pH1N1) infection, 3 were co-
infected with dengue. All three (100%) of co-infected children were hospitalized, compared
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with 1% of those with influenza A(pH1N1) infection only (p<0.001) and 42% of those with
dengue infection only (p = 0.08) [22]. The second study followed a cohort of children with den-
gue and found that 66% had antibodies to influenza A(pH1N1), suggesting recent infection
with influenza. Dengue patients with serologic evidence of recent past influenza A(pH1N1) in-
fection had nearly twofold increased odds of developing shock compared with dengue patients
without evidence of recent influenza A(pH1N1) infection [OR = 1.93, 95% confidence interval
(CI) 1.01–3.31, p = 0.045] [23].
Malaria. Titles and abstracts of 3,461 published articles were reviewed (Fig 1). Of these ar-
ticles, 669 were duplicates and were removed. The remaining 2,670 titles and abstracts were as-
sessed and 4 articles met the inclusion criteria for this review. All 4 studies assessing malaria
Fig 1. PRISMA flow diagram for systematic reviews of influenza and dengue (D), malaria (MR), measles (MS), meningococcus (MN), Pneumocystis
jirovecii pneumonia (PCP), hemoglobinopathies (H), andmalnutrition (MT).
doi:10.1371/journal.pone.0128580.g001
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and influenza co-infection were from Africa: 2 from Kenya, and 1 each from Senegal, and Tan-
zania. Malaria infection was diagnosed by blood smear in all studies. Three of the four studies
were of high quality, and all included at least 25 cases (S1 Table).
The first three studies evaluated the risk of co-infection, but not the impact on disease sever-
ity. The earliest of these studies, which was from Tanzania and had the lowest quality, used se-
rology to confirm influenza infection in 14 of 24 subjects, which was a subset of 128 subjects
clinically diagnosed with influenza [24]. Among children aged 0–9 years, 28 (62%) of 45 with
influenza also had malaria parasitemia. Among age- and village-matched asymptomatic con-
trol children, 38 (84%) of 45 had parasitemia, which was a significantly higher parasitemia
(p = 0.02) and a mean positive parasite density than influenza cases (p = 0.01). No statistically
significant differences were identified in older age groups. The remaining studies all used re-
verse transcription polymerase chain reaction to identify influenza infections. A study of chil-
dren aged 5–10 years in Kenya found that 4 (11%) of 36 subjects with influenza infection were
co-infected with malaria [25]. Likewise, influenza infection occurred in 4 (13%) of 31 children
with malaria vs 32 (40%) of 81 children without malaria infection (p = 0.04). A study in Senegal
found that among 82 episodes of acute respiratory infection in 67 children, 1 (4%) of 25 with
influenza had a malaria co-infection, while 6 (18%) of 34 children with no respiratory virus
identified had malaria (p = 0.11) [26]. Another study in Kenya found 45% (149/331) of influen-
za-positive patients were co-infected with malaria, whereas only 6% (149/2408) of malaria-pos-
itive patients were co-infected with influenza [27]. Children hospitalized for respiratory disease
and with influenza infection were less likely than those without influenza to have malaria (risk
ratio [RR], 0.57–0.76 across sites and ages), and children with malaria infection were less likely
than those without to have influenza (RR, 0.36–0.63); these findings may be because febrile
children are likely to have influenza or malaria infection, but not necessarily co-infection with
both. The authors also evaluated the severity of co-infection in this study. Among co-infected
children aged 24–59 months, hospital length of stay was 2.7 and 2.8 days longer than influen-
za-only-infected children at the 2 sites, and 1.3 and 3.1 days longer than those with malaria
only (all p< 0.01).
Measles. Our literature search yielded 3,902 articles (Fig 1). Of these, 483 were duplicates,
leaving 3,429 articles. The full text of two was reviewed, and one met selection criteria, which
was of low quality (S1 Table). This study from Italy in the 1960’s tested 68 patients with mea-
sles for influenza co-infection, as well as other respiratory pathogens. Complications such as
pneumonia or enteritis were found in 60% (9/15) of patients with measles and influenza A,
63% (5/8) of patients with measles and influenza B, but only 17% (5/30) of patients with mea-
sles and no identified respiratory viral co-infection (p = 0.03 for patients with measles and any
influenza compared with measles and no viral co-infection) [28].
Meningococcus. Our literature search yielded 2,419 articles, of which 156 were duplicates
(Fig 1). This yielded 2,263 articles; the full text of 42 were screened for eligibility, and 18 met se-
lection criteria. Of these, half (9) were of high quality and three were of low quality (S1 Table).
Six used an ecological cohort study design, though none of those were of low quality.
The association between invasive meningococcal disease and antecedent viral infection was
noted as long ago as World War I [29], though the patients in these early reports were not uni-
formly tested for influenza and meningococcus and a definitive association was not found.
More recent studies from a variety of settings have observed a temporal association between in-
fluenza and meningococcal meningitis outbreaks: influenza B in India [30], influenza A and B
in Germany [31], and influenza A in the United Kingdom [32]. Temporal associations have
been confirmed by testing patients with meningococcal disease for serologic evidence of recent
influenza infection. During concurrent outbreaks of influenza and meningococcal disease at a
mental hospital in the U.S. in 1968, patients with meningococcal disease serogroup B were
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more likely to have a fourfold or greater rise in antibody titers to influenza A than controls
[33]. Similarly, patients with meningococcal disease in England and Wales in 1989 were nearly
four times more likely than age-matched controls to have serologic evidence of recent influenza
A infection as measured by high antibody titers (OR 3.9, 95% CI 1.2–13.9) [34]. Two more re-
cent outbreaks also confirmed an association in settings where close contact likely perpetuated
transmission: a cluster of 5 matching, nongroupable meningitis cases in children who all rode
the same school bus in the U.S. had increased risk of serologic evidence of influenza B infection
as measured by high titers [35], and an outbreak of 9 cases of meningococcal serogroup C in-
fections among Greek Air Force recruits had evidence of influenza B infection, either by a four-
fold increase in antibody titers of acute and convalescent serum samples or a permanent high
antibody titer of1:64 in both serum samples [36].
Some studies have looked for evidence of any viral respiratory infection among patients
with meningococcal disease outside the setting of acute outbreaks. One study found an associa-
tion between a four-fold rise in influenza B titers and bacterial meningitis among children ad-
mitted to a hospital in the U.S.; however, this association was not specific for bacterial
meningitis caused by N.meningitidis [37]. A similar association has been identified among stu-
dents at an Air Force base in the U.S. who had meningococcal serogroup C or Y disease [38].
More recently, a number of studies have quantified the magnitude of the ecologic associa-
tions between the timing of influenza and meningococcal epidemics in a number of settings
through modelling of surveillance data from many years (Table 1). Although there has been
one study that found no ecologic association between influenza and meningococcal disease
[39], the majority of these studies found a statistically significant association [40–45]. One
study found an association only among infants less than 1 year of age [40] and another only
with meningococcal disease serogroup B [44]. Studies from Canada and Germany have found
an association between influenza A and invasive meningococcal disease that was strongest with
a 1-week lag between influenza and meningococcal disease [42, 43].
In summary, there is evidence from a number of observational studies, many of high quality,
that meningococcal disease increases in frequency following influenza.
Pneumocystis jirovecii pneumonia (PCP). Our literature search yielded 433 articles; 66
duplicates were removed, leaving 366 articles, of which none met selection criteria (Fig 1).
Co-morbidity host factors
Hemoglobinopathies. The literature review identified 327 potentially relevant articles, of
which 41 were removed as duplicates (Fig 1). We reviewed the titles and abstracts of the re-
maining 286 manuscripts, and assessed the full text of 40 articles for eligbility, of which 19 met
selection criteria. None were from the African region, and all studied sickle cell disease except
one. Six studies were immunogenicity studies so the Newcastle-Ottawa Score was not applica-
ble. Of the remaining studies, 7 were of high quality, 1 was of good quality, and 5 were of low
quality.
Four published case series of influenza infection among patients with sickle cell disease
showed that influenza can precipitate acute chest syndrome among individuals with sickle cell
disease [46–49] and that influenza A(pH1N1) may have caused more severe outcomes than
seasonal influenza when it was first identified [46]. A case series of 75 children hospitalized
with influenza A(pH1N1) in Milwaukee, Wisconsin, USA, found 16% had a hemoglobinopathy
[50]. In 2009, an outbreak of influenza A(pH1N1) occurred at a camp in the U.S. for children
with hematologic and oncologic conditions; although there was no comparison group, children
with sickle cell disease were disproportionately (82%) affected by influenza, and most (89%)
were hospitalized [51]. A study from Brazil found that sickle cell disease was not associated
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with death among patients infected with influenza A(pH1N1) [52]. A study from Spain found
that 3% of children seen in an emergency department with influenza A(pH1N1) had a hemo-
globinopathy or underlying blood disorder, and that those conditions were associated with a
nearly six-fold increased odds of admission [53]. The largest and most rigorous study of the
burden of influenza among individuals with sickle cell disease used administrative data from
four U.S. states and found that children with sickle cell disease were hospitalized with influenza
at 56 times the rate of children without sickle cell disease [54].
Patients with hemoglobinopathies have impaired immune responses, and individuals with
sickle cell anemia may develop respiratory complications such as acute chest syndrome in re-
sponse to influenza infection. Six studies evaluated whether influenza vaccine is immunogenic
among individuals with sickle cell disease (Table 2). Five studies found that influenza vaccine
was immunogenic among children and adults with seroconversion rates of 60–87% and
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seroprotection rates of 70–100% [55–59]; however, the immune response may be blunted in
children who receive chronic transfusions (90% immune response among subjects not on
chronic transfusions compared with 61% among those subjects receiving chronic transfusions)
[59]. One study in adults with sickle cell disease found impaired immune responses to trivalent
inactivated vaccine, suggesting that the long-term effects of sickle cell disease, such as splenic
atrophy, may affect immune response to vaccination [60]. Influenza vaccines are generally
considered safe among individuals with sickle cell disease; however, one study suggested a 7- to
9-fold increased risk of hospitalization for sickle cell anemia after administration of trivalent
inactivated vaccine [61]. Follow-up studies by the same group did not find increased hospitali-
zations for sickle cell crises in adults [62] or children [63] after influenza vaccination. No vac-
cine effectiveness or efficacy studies among persons with sickle cell disease have been
conducted.
We found only one article that evaluated the interaction between influenza vaccine and thal-
assemia. This study found that the 2009 influenza A(pH1N1) MF59-adjuvanted vaccine was
immunogenic and safe among adolescents and young adults with β-thalassemia [64].
In summary, a number of high quality observational studies showed that sickle cell disease
is associated with increased severity and frequency of influenza. Immunogenicity studies sug-
gest that influenza vaccine is effective among those with sickle cell disease.
Malnutrition. Titles and abstracts of 1,686 published articles were reviewed (Fig 1). Of
these articles, 422 were duplicates and were removed. The remaining 1,264 titles and abstracts
Table 2. Summary of studies evaluating influenza vaccine among individuals with hemoglobinopathies. Seroprotection was defined as >1:40
HI titers.
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were assessed using the above criteria. 37 original articles were assessed in full for eligibility
and 16 review articles were reviewed for additional references. Among the 16 articles that met
the inclusion criteria for this review, 5 assessed the impact of malnutrition in children on influ-
enza disease and 11 assessed malnutrition as a risk factor for poor response to influenza vacci-
nation in the elderly. Two studies were randomized trials, so the Newcastle-Ottawa Score was
not applicable. Of the remaining studies, eight studies were of high quality and none were low
quality (S1 Table).
A number of studies have shown that protein-energy or micronutrient malnutrition may
modify the clinical course of influenza infection in children. Two studies assessed malnutrition
during the influenza A(pH1N1) pandemic period. A study of hospitalized children in Argen-
tina found that malnutrition was a risk factor for death among children with influenza A
(pH1N1) infection [RR = 3.07 (1.46–6.48)] [65]. A second study of 74 children hospitalized
with influenza A(pH1N1) in Peru found that malnutrition was common (40%) but was not as-
sociated with severe disease [OR = 1.7 (0.4–7.2)]; in this study, the type of malnutrition was
not specified [66]. A third study among Gambian children that found few cases of influenza
among malnourished children presenting to care at an outpatient clinic (5% prevalence) and
no statistically significant difference in the prevalence of influenza between malnourished and
nourished children [67]. A randomized trial of vitamin D supplementation in Japanese chil-
dren receiving 1200 IU Vitamin D3 daily found a reduced risk of influenza A infection
(RR = 0.58, 95% CI 0.34–0.99) [68]. Lastly, a U.S. study that examined the impact of body mass
index (BMI) on influenza A(pH1N1) found that among children 2–19 years of age hospitaliza-
tion was associated with being underweight (BMI5th percentile) among those with
[OR = 12.5, (3.4–45.5)] or without [OR = 5.5, (1.3–22.5)] chronic conditions [69].
Among the elderly there were 11 studies that assessed malnutrition and nutritional supple-
mentation as a risk factor for poor immunogenic response to vaccination, as measured by hu-
moral immunity. Four articles assessed the relationship between general nutritional status and
BMI and response to influenza vaccine [70–73], but only 1 study found an association between
poor vaccine response and low BMI [73]. Other studies found statistically significant associa-
tions between markers of nutritional status including haemoglobin [71], iron [71], total protein
[71], serum albumin [74], vitamin D [75], and vitamin E [76] and poor response to influenza
vaccination. Other studies found no association between protein [77], beta-carotene [78], reti-
nol [78], alpha-tocopherol [78] or zinc [78] and response to influenza vaccination. Likewise,
two studies of zinc supplementation in the elderly found conflicting results [79, 80]. One study
found that neither zinc nor zinc plus arginine affected response to influenza immunization in
the elderly [79], while the other found that supplementation with zinc sulphate and selenium
sulfide increased seroprotection rates to influenza A(H3N2) [80].
In summary, there were a number of good or high quality studies, but the results were
mixed regarding whether there was an association between influenza and malnutrition.
Discussion
This systematic review suggests that infections and diseases more prevalent in settings such as
Africa may affect the frequency and severity of influenza infection (Table 3). Studies included
in this review suggest an association between influenza severity or frequency and sickle cell dis-
ease, dengue, and measles, though the data on the potential interaction between influenza and
dengue and measles are based few studes and the study of measles is of low quality. Influenza
infection increased the frequency of meningococcal disease. The studies on malaria and malnu-
trition found mixed results with respect to association with influenza frequency and severity.
Other infections not included in these systematic reviews, such as HIV, tuberculosis, and
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pneumococcal disease, are associated with increased severity of influenza. We found no data
on influenza and PCP. Many of the studies were not of high quality. More high quality studies
should be conducted in lower income settings and African countries to confirm these associa-
tions. Although influenza has long been under-recognized as a cause of illness and death in Af-
rica, this review suggests that prevention and vaccination against influenza can prevent severe
influenza infection in these high-risk and co-infected groups.
Although HIV was not included in this review, it is epidemic in many sub-Saharan countries
[81], and recent reviews found that HIV and AIDS are associated with increased severity of in-
fluenza [14, 82]. In adults in the U.S., HIV is associated with increased severity [83] and mor-
tality [84] among patients with influenza. HIV-infected adults in Kenya have been found to
have increased odds of hospitalization for pneumonia [85]. HIV-infected children in South Af-
rica have an increased risk of hospitalization for pneumonia [86, 87]. In South Africa, HIV
confers increased odds of death from influenza-associated pneumonia in all ages [8, 88], and
the HIV epidemic drives the epidemiology and clinical presentation of influenza [8, 89].
Influenza can be a risk factor for other infections. As has been shown with pneumococcal
disease [15, 16], influenza appears to increase an individual’s susceptibility to meningococcal
disease. Similarly, tuberculosis is epidemic in many sub-Saharan countries [81], and influenza
may be associated with an increased risk of death from tuberculosis [90, 91]. Mortality data
from the 1918 influenza pandemic and more recent data from South Africa suggest that death
from tuberculosis may be precipitated by co-infection with influenza [17, 91].
Social and environmental factors may increase the risk of severe influenza in settings like
Africa. As classified by World Bank, all of sub-Saharan African countries are low- or middle-
income countries [92], and lower socioeconomic status is associated with increased severity
and burden of influenza disease [93–95]. Chronic diseases such as diabetes mellitus and lung
Table 3. Associations of co-infections and co-morbidities prevalent in Africa with increased severity or incidence of influenza.
Co-infection or co-morbidity Evidence of association






increases the frequency of











Yes [50, 51, 54] No Yes
HIV Yes [8, 14, 82, 87] Yes [8, 14, 82, 83] No No
Malaria Yes [27] No [24–27] No Yes
Malnutrition Unclear (one study found
an association [65] and one
did not [66])
Unclear (two studies found
an association [68, 69] and
one did not [67])
No Yes
Measles Yes [28] No studies No Yes
Meningococcal disease No studies No Yes [30–38, 40–45] (One study
[39] did not find an association)
Yes
Pneumococcal disease Yes [15, 16] No Yes [15, 16] No
Pneumocystis jirovecii pneumonia
(PCP)
No studies No studies No Yes
Tuberculosis Yes [17, 91] Yes [8, 17, 91] No No
Underlying medical conditions,
such as diabetes mellitus and
asthma
Yes [19] Yes [19] No No
Applicable references from the systematic review and the literature are included.
doi:10.1371/journal.pone.0128580.t003
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disease are also common in Africa, and may affect influenza [19]. Low birth weight and non-
exclusive breast feeding are common in sub-Saharan Africa [81]. Solid fuel use is common in
sub-Saharan Africa and leads to exposure to indoor air pollution. Low birth weight, non-exclu-
sive breast feeding and exposure to indoor air pollution are associated with pneumonia, if not
with influenza specifically [96–98].
Some infectious diseases common in Africa may make the diagnosis of influenza challeng-
ing because of similar clinical presentations. Malaria and dengue can present clinically with fe-
brile syndromes similar to influenza [99], and co-infection has been reported [100–104].
Although measles and PCP are common in Africa, can present as febrile respiratory illness,
and may be associated with changes in the immune system, we found too few published articles
to comment on the interaction of those infections with influenza. If there is an association be-
tween PCP and influenza infection, it may be difficult to tease out the effects of underlying
HIV infection since the majority of patients with PCP will also have HIV infection.
The main limitation of these reviews are the paucity of high quality published articles in
some areas—namely dengue, measles, and PCP—which limit the conclusions that can be
drawn. Nearly all of the studies use an observational study design, including ecological cohort
studies of influenza and meningococcus. Although many of these observational studies were of
high quality, and randomized controlled trials would not be ethical or feasible to answer many
of these research questions, observational studies are subject to biases. Except for the publica-
tions on malaria, most of the published articles are from countries not in Africa, so the findings
may not be generalizable to low-income and African settings. For example, only one study eval-
uating the association between meningococcal disease and respiratory viruses has been con-
ducted in Africa; although there was a statistically significant association found, the viruses
evaluated (adenovirus, parainfluenza, respiratory syncytial virus, and rhinovirus) did not in-
clude influenza [105]. This is also not a comprehensive review of every condition that might
impact influenza in Africa. Some of the articles may use less effective laboratory techniques to
identify influenza, particularly older studies that were conducted before more sensitive and
specific techniques, such as polymerase chain reaction for influenza, were developed or com-
monly used; this may misclassify some patients with influenza as not having influenza. Studies
used differing definitions of immune response, either high titers or a four-fold response, which
may make it difficult to interpret and determine active co-infection. Lastly, many of the studies
did not control for potential confounding factors such as other infections (e.g., HIV), severity
at presentation, and health care access and did not include comparison groups to adequately
address the research question.
Vaccination against influenza remains the most important and effective way to prevent dis-
ease from influenza. Very little influenza vaccine is available and used in sub-Saharan Africa
[106]. Vaccinating populations at high risk of severe complications, such as individuals with
HIV infection, tuberculosis, and sickle cell disease, should be prioritized in countries where
those conditions are prevalent. Although there are few studies demonstrating the efficacy or ef-
fectiveness of influenza vaccine among individuals who are infected with tuberculosis, influen-
za vaccine is safe and effective among adults that are infected with HIV [107] and those that
have sickle cell disease [55–59]. Since influenza can predispose individuals to pneumococcal
and meningococcal disease, vaccination against those pathogens may reduce the burden of
these secondary bacterial infections and be important in minimizing disease seasonally [108]
and during a pandemic [109]. Prevention and treatment of other diseases such as HIV with an-
tiretrovirals will also be an essential component to controlling influenza in settings with high
HIV prevalence. Micronutrient supplementation may also be useful, particularly in settings
with malnutrition, although micronutrient interventions would be unlikely to be implemented
for influenza only. Clinicians must not forget that influenza can cause severe disease in settings
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such as Africa, and policymakers should consider how to best control the disease in their coun-
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